Transactions
Evolution Research Group acquired by Linden Capital Partners
May. 2018
Client: Evolution Research Group is one of the largest independent clinical research site companies in North America
Role: Edgemont Partners acted as co-advisor to Evolution Research Group in its sale to Linden Capital Partners
Location: Watchung, NJ
Sector: Pharmaceutical Services
Lead Banker: David Blume
acquired by
Case Study
Evolution Research Group acquired by Linden Capital Partners
To deliver maximum value for Evolution Research Group’s (ERG) shareholders throughout the course of its initial formation, subsequent roll-up acquisition strategy, and eventual sale.
ERG was focused on not only increasing its capabilities and scale, but also its value—and we served as its financial advisor every step of the way. From advising on which initial companies should merge to form the new ERG entity to the later acquisition of six additional businesses, a strategic purchase by DFW Capital, and years of bolt-on and strategic acquisition transactions, we provided recommendations for ERG, never losing sight of the bigger picture when making decisions.
That big-picture thinking ultimately came into play eight years after ERG’s formation. DFW Capital was looking to sell its now-consolidated portfolio company and, once again, selected us to advise the transaction due to our long-standing relationship with the firm. Having already increased ERG’s value immensely through those previous transactions, the company was in a strong position for sale. We advised—and then implemented—a broad auction process to ensure strong bidding and successful results.
ERG was sold to Linden Capital Partners at a premium valuation. With a history that includes over 5,000 clinical trials across a wide range of areas, from the central nervous system to sleep disorders to addiction, ERG will now have access to even more resources—helping them extend this critical work to other studies in the future.